MedChem by Design 2017

CCG is hosting a 1-day meeting focusing on benefits of computer-aided ligand and structure-based drug design techniques for medicinal chemists. Short hands-on workshops in the morning will be followed by scientific presentations in the afternoon. The meeting will end with a social reception. Please note that space is limited so early registration is recommended.

• MOEsaic: Application of Matched Molecular Pairs to Interactive SAR Exploration
  Al Ajamian, Director, Chemical Computing Group
• Interdiction at a Protein-Protein Interface: Structure-Based Design of the Mcl-1 Inhibitor AMG 176
  Sean Brown, Principal Scientist, Amgen
• Discovery of M2951, a selective, covalent inhibitor of BTK for the treatment of autoimmune diseases
  Andreas Goutopoulos, Senior Director- Chemistry, EMD Serono, Inc.
• Utilization of Structure-Based Design to Identify Novel, Covalent Inhibitors of T790M EGFR
  Edward J. Hennessy, Associate Principal Scientist, AstraZeneca
• Phenotypic screening for the discovery of novel small molecules and targets to treat neurodegenerative diseases
  Matt Lucas, Director of Chemistry, Yumanity Therapeutics
• Talk title to be announced
  Chris Yates, Director of Medicinal Chemistry, Viamet Pharmaceuticals

There is no cost to attend but pre-registration is required as seats are limited. Registrations will be processed and accepted on a first-come, first-serve basis.

• Alain Deschenes, Chemical Computing Group
• Igor Mochalkin, EMD Serono
• Michael Hale, Ra Pharmaceuticals
• Raul Alvarez, Chemical Computing Group